Please login to the form below

Not currently logged in
Email:
Password:

Merck melanoma drug approved

The US Food and Drug Administration has granted marketing approval to Merck's Sylatron (peginterferon alfa-2b) melanoma treatment

The US Food and Drug Administration (FDA) has granted marketing approval to Merck's Sylatron (peginterferon alfa-2b) melanoma treatment.

The drug, which is injected subcutaneously, is indicated for the adjuvant treatment of node-positive melanoma. Specifically, it has been cleared for use within 84 days of definitive surgical resection including complete lymphadenectomy for the treatment of melanoma with microscopic or gross nodal involvement. Patients can self-inject the drug once a week, Merck noted.

The approval was based on a single, open-label trial of 1,256 patients who had had surgery and were randomised to receive either Sylatron or observation for five years.

The primary efficacy endpoint was relapse-free survival, which had an estimated median time of 34.8 months in the treatment group and 25.5 months in the observation-only group. There was no difference in overall survival between the Sylatron and the observation arms.

The drug was developed by Schering-Plough and became part of Merck's pipeline when the two companies merged.

Sylatron is the second significant new drug for melanoma to win FDA approval in recent weeks. Last month, the FDA approved Bristol-Myers Squibb's Yervoy (ipilimumab) for the treatment of unresectable or metastatic melanoma, noting that the therapy demonstrates a 'significant improvement' in overall survival for patients whose skin cancer cannot be treated with surgery or has spread to other organs.

12th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics